Whole fruit and medolla powder of Elaeagnus angustifolia effect on osteoarthritis

Effect of whole fruit and medolla powder of Elaeagnus angustifolia supplementation on clinical manifestation, inflammatory factors, matrix metalloproteinase enzymes, oxidative stress and nutritional status of patients with knee osteoarthritis

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT201208241197N13

Enrollment

Registered

2013-04-14

Start date

2013-04-01

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

knee osteoarthritis. Bilateral primary osteoarthritis of knee

Interventions

Intervention 1: Intervention 1: Oral administration of 15 grams whole fruit powder of Elaeagnus angustifolia (prepared by the researcher) for 8 weeks. Intervention 2: Intervention 2: Oral administrati

Treatment - Other

Placebo

Intervention 1: Oral administration of 15 grams whole fruit powder of Elaeagnus angustifolia (prepared by the researcher) for 8 weeks

Intervention 2: Oral administration of 15 grams medolla powder of Elaeagnus angustifolia (prepared by the researcher) for 8 weeks

Intervention3: Oral administration of 15 grams corn starch+Isomaltose for 8 weeks

Eligibility

Sex/Gender

Female

Age

40 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: 1.Female 2.Age: 40-70 years 3.Bilateral primary osteoarthritis of knee (according to ACR classification) 4.Body mass index of 25-29.9 Exclusion criteria: 1.Secondary osteoarthritis 2.Active synovitis 3.Neurological disorder that affects movement, muscle control and balance 4.Uncontrolled hypertension, diabetes, cardiovascular disorders, chronic kidney disorders and functional liver disorders 5.Using Frosemid, Probenecid, Anticoagulants, Hydantoin, Sulfonamides, Methotrexate, Lithium salts, Beta blockers and muscle relaxants 6.Smoking 7.Having an allergic reaction to Elaeagnus angustifolia 8. Daily use of Elaeagnus Angustifolia

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Pain. Timepoint: Onset and after the study. Method of measurement: WOMAC questionnaire.;Joint stiffness. Timepoint: Onset and after the study. Method of measurement: WOMAC questionnaire.;Disability. Timepoint: Onset and after the study. Method of measurement: WOMAC questionnaire.	—

Secondary

Measure	Time frame
Plasma total antioxidant capacity and MDA level. Timepoint: Onset and at the end of the study. Method of measurement: Antioxidant capacity = Randox kit, MDA= Fluorometry.;Serum IL-1, IL-10 and TNF-alpha levels. Timepoint: Onset and at the end of the study. Method of measurement: IL-1:ELISA kit; IL-10:ELISA kit; TNF-alpha: ELISA kit.;Serum MMP-1 and MMP-13 levels. Timepoint: Onset and at the end of the study. Method of measurement: MMP-1:ELISA kits; MMP-13:ELISA kit.;Nutritional status and dietary intake. Timepoint: Onset and at the end of the study. Method of measurement: Dietary intake: 24 hours questionnaires; Nutritional status: Weight: Standard scale, Height: Stadiometer.	—

Measure

Time frame

Plasma total antioxidant capacity and MDA level. Timepoint: Onset and at the end of the study. Method of measurement: Antioxidant capacity = Randox kit, MDA= Fluorometry.;Serum IL-1, IL-10 and TNF-alpha levels. Timepoint: Onset and at the end of the study. Method of measurement: IL-1:ELISA kit; IL-10:ELISA kit; TNF-alpha: ELISA kit.;Serum MMP-1 and MMP-13 levels. Timepoint: Onset and at the end of the study. Method of measurement: MMP-1:ELISA kits; MMP-13:ELISA kit.;Nutritional status and dietary intake. Timepoint: Onset and at the end of the study. Method of measurement: Dietary intake: 24 hours questionnaires; Nutritional status: Weight: Standard scale, Height: Stadiometer.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactZeinab Nikniaz

Nutrition faculty, Tabriz University of Medical Sciences.

znikniaz@hotmail.com+98 41 1334 1113

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026